Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis.

Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED.

Cardiol J. 2011;18(5):503-14. Review. Erratum in: Cardiol J. 2012;19(4):442.

2.

Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.

Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):706-13. doi: 10.1161/CIRCEP.112.970798. Epub 2012 Jun 8.

3.

Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.

Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T.

Circ Cardiovasc Qual Outcomes. 2009 Jan;2(1):16-24. doi: 10.1161/CIRCOUTCOMES.108.807123. Epub 2009 Jan 6.

4.

Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.

Forleo GB, Della Rocca DG, Papavasileiou LP, Panattoni G, Sergi D, Duro L, Mahfouz K, Magliano G, Santini L, Romeo F.

J Cardiovasc Med (Hagerstown). 2011 Nov;12(11):779-84. doi: 10.2459/JCM.0b013e32834ae458.

PMID:
21941203
5.

Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis.

Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M.

Circ Heart Fail. 2012 Sep 1;5(5):552-9. Epub 2012 Jul 20. Review.

6.

Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306. Epub 2015 Feb 10.

7.

Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.

Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, Køber L, Thune JJ.

Circulation. 2017 Nov 7;136(19):1772-1780. doi: 10.1161/CIRCULATIONAHA.117.028829. Epub 2017 Sep 6.

PMID:
28877914
8.

Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.

Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV.

Circ Arrhythm Electrophysiol. 2014 Feb;7(1):164-70. doi: 10.1161/CIRCEP.113.001217. Epub 2014 Jan 20. Review.

9.

Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).

Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S, Eldadah Z, Ellenbogen KA, Dickfeld T, Spragg DD, Marine JE, Guallar E, Tomaselli GF.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1084-91. doi: 10.1161/CIRCEP.113.001705. Epub 2014 Oct 1.

10.

Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.

Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.

J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):883-9. doi: 10.1111/j.1540-8167.2009.01716.x. Epub 2010 Feb 1.

PMID:
20132378
11.

Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.

Fröhlich GM, Holzmeister J, Hübler M, Hübler S, Wolfrum M, Enseleit F, Seifert B, Hürlimann D, Lehmkuhl HB, Noll G, Steffel J, Falk V, Lüscher TF, Hetzer R, Ruschitzka F.

Heart. 2013 Aug;99(16):1158-65. doi: 10.1136/heartjnl-2013-304185. Epub 2013 Jun 27.

PMID:
23813845
12.

Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.

Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV Jr, Navaneethan SD.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1119-27. doi: 10.2215/CJN.11121114. Epub 2015 Jun 25.

13.

Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.

Sanders GD, Kong MH, Al-Khatib SM, Peterson ED.

Am Heart J. 2010 Jul;160(1):122-31. doi: 10.1016/j.ahj.2010.04.021.

PMID:
20598982
14.

Assessment on Implantable Defibrillators and the Evidence for Primary Prevention of Sudden Cardiac Death [Internet].

Uhlig K, Balk EM, Earley A, Persson R, Garlitski AC, Chen M, Lamont JL, Miligkos M, Avendano EE.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun 26.

15.

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Khazanie P, Hellkamp AS, Fonarow GC, Bhatt DL, Masoudi FA, Anstrom KJ, Heidenreich PA, Yancy CW, Curtis LH, Hernandez AF, Peterson ED, Al-Khatib SM.

J Am Heart Assoc. 2015 Aug 6;4(8):e002061. doi: 10.1161/JAHA.115.002061.

16.

Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.

Stockburger M, Krebs A, Nitardy A, Habedank D, Celebi O, Knaus T, Dietz R.

Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S16-20. doi: 10.1111/j.1540-8159.2008.02222.x.

PMID:
19250084
17.

The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death.

Henyan NN, White CM, Gillespie EL, Smith K, Coleman CI, Kluger J.

J Intern Med. 2006 Nov;260(5):467-73.

18.

Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.

Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E, Rangel-Sousa D, Esteve-Ruiz IM, Martínez-Martínez A.

Transplant Proc. 2013;45(10):3659-61. doi: 10.1016/j.transproceed.2013.10.017.

PMID:
24314988
19.

Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.

DeWitt ES, Triedman JK, Cecchin F, Mah DY, Abrams DJ, Walsh EP, Gauvreau K, Alexander ME.

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1057-63. doi: 10.1161/CIRCEP.114.001569. Epub 2014 Sep 27.

20.

Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials.

Ezekowitz JA, Armstrong PW, McAlister FA.

Ann Intern Med. 2003 Mar 18;138(6):445-52. Review.

PMID:
12639076

Supplemental Content

Support Center